Take Care to offer Core Performance wellness services to employer clients
DEERFIELD, Ill. — Walgreens and Take Care Health Systems have entered into a relationship with Core Performance to offer Core Performance corporate wellness services to Take Care Health Systems employer clients and bolster its service portfolio.
Take Care Health Systems is the nation’s largest manager of employer health, pharmacy and fitness centers, with nearly 400 locations throughout the United States. As part of the agreement, Walgreens has made a minority investment in Core Performance.
Core Performance offers wellness, fitness and nutrition programs developed by Athletes’ Performance, a resource for athlete training. Core Performance systems are designed to drive employee engagement and measurable wellness results through the development of personalized plans that are designed to empower an organization’s employees to change how they look, feel and perform at work and in life.
Core Performance programs can incorporate an array of elements, including Web-based instruction and results tracking, on-site fitness centers and workplace activation through health-and-wellness coaches with expertise in the Athletes’ Performance methodology.
"Walgreens and Take Care Health Systems have a track record of bringing cutting-edge pharmacy, health and wellness solutions to employers," stated Peter Hotz, Walgreens group VP. "An affiliation with Core Performance strengthens our service portfolio by enabling our clients to access and benefit from the expertise and methodology of one of the world’s foremost fitness, nutrition and performance providers. This comprehensive suite of offerings has the potential to drive a significant return for employers while improving the lives of their workforce."
According to Fuld & Co. research, employer health centers can offer employers savings of 10% to 30% on healthcare costs. The facilities generate savings by reducing costs for healthcare services, increasing productivity among the workforce and improving the overall health and well-being of the employee population.
Exenatide improves glucose control among diabetes patients in mid-stage trial
SAN DIEGO — A once-monthly formulation of a drug made by Amylin Pharmaceuticals, Eli Lilly and Alkermes improved glucose control in patients with Type 2 diabetes, according to results of a mid-stage clinical trial presented at the American Diabetes Association’s 71st Scientific Sessions.
The three companies said once-monthly injections of the drug exenatide improved blood-sugar control and produced modest weight loss in the 121-patient phase-2 study.
Exenatide is the active ingredient of Byetta, which Amylin markets under an agreement with Lilly and Bydureon, a once-weekly formulation of Byetta currently undergoing regulatory review.
Amneal’s president, CEO win Ernst & Young Entrepreneur of the Year award
BRIDGEWATER, N.J. — Chirag Patel and Chintu Patel, who respectively are the president and CEO of Amneal Pharmaceuticals, recently received the Ernst & Young Entrepreneur of the Year award.
The executives received the 2011 New Jersey Award in the pharmaceutical and medical technology category, which was presented at a gala event last month.
As Ernst & Young Entrepreneur of the Year 2011 New Jersey Award winners, Chintu and Chirag Patel, who cofounded Amneal in 2002, now are eligible for consideration for the Ernst & Young Entrepreneur of the Year 2011 national award. Award winners will be announced at the annual awards gala in Palm Springs, Calif., on Nov. 12.